UK · Research-grade · Cold-chain

BPC-157 side effects — what the research actually shows.

The most-studied healing peptide in the space has one honest problem: the evidence is strong in animals and thin in humans. Here's the full, unvarnished picture — what the preclinical data shows, what the side-effect list actually contains, and what grade D evidence means before you buy.

01 · What it is

The healing peptide, in plain terms

The molecule and the mechanism, from the product page.

In plain terms

It speeds up the body's repair machinery at an injury — more new blood vessels, more collagen, calmer inflammation — in gut, tendon, ligament and skin. That's why it's the go-to in wound and connective-tissue research circles.

Technically

BPC-157 (Body Protection Compound) is a 15-amino-acid gastric pentadecapeptide derived from a protective stomach protein. Mechanistically it's a pro-angiogenic cascade — VEGF/VEGFR2, eNOS/NO signalling, FAK/integrin, collagen deposition — that modulates chronic inflammation (iNOS) without suppressing vasodilation (eNOS).

02 · The evidence

Grade D — say it like it is

This is the section most 'results' content skips. It's the whole reason this is a research peptide.

What's strong

Strong, consistent preclinical data — rodent wound-closure and cartilage studies. The mechanism work (angiogenesis, collagen deposition, inflammation modulation) is well-replicated in animal models.

What's thin

Very few controlled human trials yet. Grade D on the product page's own scale. That's not a weakness to argue away — it's the niche the product serves: research-grade, for researchers, ahead of the human data.

03 · Side effects

The full list, honest and complete

From the product page. Shorter list than the GLP-1 class — with one theoretical caution to know about.

1
Generally well-tolerated

In animal and observational use, tolerance is the headline. That's the honest base rate — it's a healing peptide, not a class with a GI reputation.

2
Injection-site irritation

The common one. Local to the injection — the same category as any injectable, and why local-to-injury use is the typical pattern.

3
Theoretical angiogenesis caution

In vascular/tumour-prone cases, the pro-angiogenic mechanism is the reason to pause and think. Unproven as a side effect — it's a caution from the mechanism, and the product page labels it exactly that.

04 · Dosing

Typical research use, with the hedge

From the product page — typical research/clinical ranges, not a prescription.

ParameterTypical research rangeNote
Dose250–500 µg/dayDaily, not weekly — a different cadence from the GLP-1 class.
RouteOften local to the injuryThe typical pattern in the research use described on the product page.
Cycle8–16 weeksCourse-based, not indefinite.
The hedge, every time: typical research/clinical ranges — not a prescription. The classic pairing is TB-500 (thymosin beta-4 — cell-migration/anti-fibrotic) as an injury stack; the product page describes them as often used together.
05 · Ordering

How to order it

Per-vial pricing, two payment paths, same delivery as the rest of the range.

1
Per-vial pricing, no minimums

5 mg and 10 mg vials, from £9.35 — order one vial or a full course, the per-vial price is the same.

2
Bank transfer — save 10%

Same lot, same delivery, whole order 10% off. Quote your order number as the payment reference.

3
COA in the box, cold-chain to your door

Every batch ships with its Certificate of Analysis — tracked, insured, UK-wide, next working day dispatch. WELCOME10 stacks on your first order.

Research-use positioning: supplied from GMP-grade sources with a COA in the box. Not a licensed medicine and not for direct human consumption. Dosing shown = typical research/clinical ranges, not a prescription.
06 · Straight answers

The questions people actually ask

What is BPC-157 used for?
Most commonly tendon/ligament repair, post-surgical healing, gut repair (ulceration, IBD-adjacent) and osteoarthritis research. It's the standard 'healing' peptide in the space — the product page calls it the go-to for tendon, ligament, gut and post-surgical repair work.
How strong is the evidence?
Honest answer: evidence grade D. Strong, consistent preclinical — rodent wound-closure and cartilage data — but very few controlled human trials yet. That's exactly the research niche it serves, and we supply it research-grade with a COA.
What are the actual side effects?
Generally well-tolerated in animal and observational use. Injection-site irritation is the common one. There's a theoretical angiogenesis caution in vascular/tumour-prone cases — unproven, but it's the one to know before you start.
What's a typical research dosing?
250–500 µg/day, often local to the injury, in 8–16 week cycles. Typical research/clinical ranges — not a prescription. The classic pairing is TB-500 for an injury stack.
How do I order it?
Per-vial pricing — 5 mg vials from £9.35, no minimums. Bank transfer takes 10% off (quote your order number as the reference), WELCOME10 stacks on your first order, and every batch ships cold-chain with its COA.
07 · Don't miss a restock

Restock alerts + first-order tips, no list-of-emails

One useful email when a vial needs replacing, plus the bits that save you the vial. No pressure, unsubscribe anytime.